

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated November 12, 2015,
1. Spring Hill Cardiology, PLLC	3. License number 47-25411-02 is amended in its entirety to read as follows:
2. 428 Division Street Suite 1A Charleston, WV 25309-1469	4. Expiration date September 30, 2022
	5. Docket No. 030-38571 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 428 Division Street, Suite 1A, Charleston, West Virginia,
11. The Radiation Safety Officer for this license is Mark Younis, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
47-25411-02Docket or Reference Number
030-38571

Amendment No. 2

- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Marvin Abdalah, M. D.	35.100; 35.200
David Abramowitz, M.D.	35.100; 35.200
Riad Al-Asbahi, M.D.	35.100; 35.200
John J. Anton, M.D.	35.100; 35.200
James Baek, M.D.	35.100; 35.200
Carl P. Binns, M.D.	35.100; 35.200
Timothy Conner, M.D.	35.100; 35.200
Ronald Cordell, M.D.	35.100; 35.200
Kenneth Dwyer, M.D.	35.100; 35.200
Ravindra K. Goginerni, M.D.	35.100; 35.200
Omar Hallak, M.D.	35.100; 35.200
Henry Haven, M.D.	35.100; 35.200
Johnsey Leef, M.D.	35.100; 35.200
A Jane Maloof, M.D.	35.100; 35.200
Mary McJunkin, M.D.	35.100; 35.200
John F Mega, M.D.	35.100; 35.200
Frank Muto, M.D.	35.100; 35.200
Joseph E. Pate, M.D.	35.100; 35.200
Pamela M. Phillips, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-25411-02

Docket or Reference Number
030-38571

Amendment No. 2

<u>Authorized Users</u>	<u>Material and Use</u>
John Reifsteck, M.D.	35.100; 35.200
Christopher Schlarb, M.D.	35.100; 35.200
Joseph Skeens, M.D.	35.100; 35.200
James Smith, M.D.	35.100; 35.200
Robert Smith, M.D.	35.100; 35.200
David Sparks, M.D.	35.100; 35.200
John Willis, M.D.	35.100; 35.200
Mark Younis, M.D.	35.100; 35.200
Bassam Moushmoush, M.D.	35.200
Ahmed M. Sakkal, M.D.	35.200
Mohammed Yaser Haffar, M.D.	35.200
Mohammad Hussan Pervaiz, M.D.	35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-25411-02

Docket or Reference Number
030-38571

Amendment No. 2

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated August 14, 2012 (except Item 9.1)

[ML12242A473]

B. Letter dated November 12, 2015

[ML15334A431]

For the U.S. Nuclear Regulatory Commission

Date February 5, 2016

By ***Original signed by Penny Lanzisera***

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety